KYNTRA BIO, INC. (KYNB) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $556.0K | -96.4% |
| 2024 | $15.56M | +292.8% |
| 2023 | $3.96M | -80.5% |
| 2022 | $20.28M | +57.6% |
| 2021 | $12.87M | +45.1% |
| 2020 | $8.87M | +673.2% |
| 2019 | $1.15M | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $556.0K | -96.4% |
| 2024 | $15.56M | +292.8% |
| 2023 | $3.96M | -80.5% |
| 2022 | $20.28M | +57.6% |
| 2021 | $12.87M | +45.1% |
| 2020 | $8.87M | +673.2% |
| 2019 | $1.15M | — |